nach oben

Current Hypertension Reports

Erschienen in:

01.06.2010

Angiotensin-Converting Enzyme 2: Central Regulator for Cardiovascular Function

verfasst von: Huijing Xia, Eric Lazartigues

Erschienen in: Current Hypertension Reports | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Angiotensin-converting enzyme 2 (ACE2) is a new component of the renin-angiotensin system (RAS). Accumulating evidence shows that ACE2 provides protective effects in peripheral tissues and has great potential for the treatment of RAS-related diseases. The role of ACE2 in the central nervous system is not well established. However, in recent years, much more progress has been made on the studies of this carboxypeptidase in the central regulation of blood pressure and cardiovascular function in general. It has been shown that brain ACE2 interacts with the other components of the RAS (ACE, angiotensin II, and angiotensin II type 1 receptor), protects baroreflex and autonomic function, stimulates nitric oxide release, reduces oxidative stress, and prevents the development of or attenuates hypertension. These data support the critical role of ACE2 in the central regulation of cardiovascular function. This review summarizes recently published data on the central effects of ACE2 in the regulation of cardiovascular function.

Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86:747–803.CrossRefPubMed

Tipnis SR, Hooper NM, Hyde R, et al.: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000, 275:33238–33243.CrossRefPubMed

Donoghue M, Hsieh F, Baronas E, et al.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000, 87:E1–E9.PubMed

Vickers C, Hales P, Kaushik V, et al.: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002, 277:14838–14843.CrossRefPubMed

Ferrario CM, Trask AJ, Jessup JA: Advances in the biochemical and functional roles of angiotensin converting enzyme 2 and angiotensin-(1-7) in the regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005, 289:H2281–H2290.CrossRefPubMed

Xia H, Lazartigues E: Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem 2008, 107:1482–1494.CrossRefPubMed

Phillips MI, de Oliveira EM: Brain renin angiotensin in disease. J Mol Med 2008, 86:715–722.CrossRefPubMed

Nagata S, Kato J, Sasaki K, et al.: Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 2006, 350:1026–1031.CrossRefPubMed

Harmer D, Gilbert M, Borman R, et al.: Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002, 532:107–110.CrossRefPubMed

10.

Hamming I, Timens W, Bulthuis MLC, et al.: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004, 203:631–637.CrossRefPubMed

11.

Doobay MF, Talman LS, Obr TD, et al.: Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007, 292:R373–R381.PubMed

12.

• Lin Z, Chen Y, Zhang W, et al.: RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2. Exp Physiol 2008, 93:676–684. Using adenovirus vectors carrying small, hairpin RNA for AT1a or AT1b, the authors demonstrated that downregulated AT1a mRNA in the mouse brainstem resulted in decreased ACE2 mRNA expression in this region, whereas reduction in AT1b mRNA had no effect on ACE2.

13.

Phillips MI, Sumners C: Angiotensin II in central nervous system physiology. Regul Pept 1998, 78:1–11.CrossRefPubMed

14.

Tan J, Wang H, Leenen FH: Increases in brain and cardiac AT1 receptor and ACE densities after myocardial infarct in rats. Am J Physiol Heart Circ Physiol 2004, 286:H1665–H1671.CrossRefPubMed

15.

Campagnole-Santos MJ, Heringer SB, Batista EN, et al.: Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol 1992, 263:R89–R94.PubMed

16.

Heringer-Walther S, Batista EN, Walther T, et al.: Baroreflex improvement in SHR after ace inhibition involves angiotensin-(1-7). Hypertension 2001, 37:1309–1314.PubMed

17.

Gironacci MM, Valera MS, Yujnovsky I, et al.: Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension 2004, 44:783–787.CrossRefPubMed

18.

Dobruch J, Paczwa P, Lon S, et al.: Hypotensive function of the brain angiotensin-(1-7) in Sprague Dawley and renin transgenic rats. J Physiol Pharmacol 2003, 54:371–381.PubMed

19.

Höcht C, Gironacci MM, Mayer MA, et al.: Involvement of angiotensin-(1-7) in the hypothalamic hypotensive effect of captopril in sinoaortic denervated rats. Regul Pept 2008, 146:58–66.CrossRefPubMed

20.

Lu J, Zhang Y, Shi J: Effects of intracerebroventricular infusion of angiotensin-(1-7) on bradykinin formation and the kinin receptor expression after focal cerebral ischemia-reperfusion in rats. Brain Res 2008, 1219:127–135.CrossRefPubMed

21.

Bomtempo CA, Santos GF, Santos RA, et al.: Interaction of bradykinin and angiotensin-(1-7) in the central modulation of the baroreflex control of the heart rate. J Hypertens 1998, 16:1797–1804.CrossRefPubMed

22.

Gironacci MM, Vatta M, Rodriguez-Fermepin M, et al.: Angiotensin-(1-7) reduces norepinephrine release through a nitric oxide mechanism in rat hypothalamus. Hypertension 2000, 35:1248–1252.PubMed

23.

Dean RG, Burrell LM: ACE2 and diabetic complications. Curr Pharm Des 2007, 13:2730–2735.CrossRefPubMed

24.

Raizada MK, Ferreira AJ: ACE2: A new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007, 50:112–119.CrossRefPubMed

25.

Ferreira AJ, Raizada MK: Genomic and proteomic approaches for targeting of angiotensin-converting enzyme 2 for cardiovascular diseases. Curr Opin Cardiol 2008, 23:364–369.CrossRefPubMed

26.

Lambert DW, Hooper NM, Turner AJ: Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol 2008, 75:781–786.CrossRefPubMed

27.

Ingelfinger JR: Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009, 18:79–84.CrossRefPubMed

28.

Yamazato M, Yamazato Y, Sun C, et al.: Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 2007, 49:926–931.CrossRefPubMed

29.

• Diz DI, Garcia-Espinosa MA, Gegick S, et al.: Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol 2008, 93:694–700. Using an ACE2 inhibitor, MLN4760, in Sprague Dawley rats, the authors showed that inhibition of ACE2 activity in the NTS impaired the baroreflex sensitivity for control of heart rate in response to increases in arterial pressure. Moreover, there was no further reduction of these effects following combined Ang-(1-7) receptor blockade and ACE2 inhibition, suggesting that ACE2 is the main enzyme forming Ang-(1-7).

30.

Feng Y, Yue X, Xia H, et al.: Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res 2008, 102:729–736.CrossRefPubMed

31.

•• Xia H, Feng Y, Obr TD, et al.: Angiotensin II type 1 receptor mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension 2009, 53:210–216. Using a chronically hypertensive model and a triple-transgenic model with chronic overexpression of Ang II and brain ACE2, the authors found that AT1R exerts an inhibitory effect on ACE2 activity in the brain of hypertensive mice, and that brain selective overexpression of ACE2 attenuated the hypertension by improving arterial baroreflex and autonomic function.

32.

Xiao L, Gao L, Zucker IH: Angiotensin-converting enzyme 2 attenuates the angiotensin II-induced upregulation of angiotensin II type 1 receptor in CATH.a neurons. Hypertension 2009, 54:e70.

33.

•• Feng Y, Xia H, Cai Y, et al.: Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res 2010, 106:373–382. Using a new transgenic mouse model (syn-hACE2) with neuron-targeted ACE2 overexpression, the investigators demonstrated that ACE2 overexpression attenuates the development of Ang II–induced hypertension by preventing the decrease in baroreflex sensitivity and parasympathetic tone. In addition, these protective effects could be mediated by increased NO availability in the brain, likely resulting from Mas and AT2R upregulation.

34.

Kar S, Gao L, Zucker IH: Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing induced chronic heart failure. J Appl Physiol. 2010 Jan 21 [Epub ahead of print].

35.

Kawajiri M, Mogi M, Higaki N, et al.: Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler 2009, 15:262–265.CrossRefPubMed

36.

Sriramula S, Cardinate JP, Lazartigues E, et al.: Bilateral ACE2 overexpression in the PVN attenuates angiotensin II-induced blood pressure response. Hypertension 2009, 54:e97.

37.

Merrill DC, Thompson MW, Carney CL, et al.: Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J Clin Invest 1996, 97:1047–1055.CrossRefPubMed

38.

Cangussu LM, Silva JR, Alzamora AC, et al.: Increased hypothalamus expression of ACE2 and Mas receptor mRNA in renovascular hypertensive rats submitted to exercise training. [abstract No. 930]. Presented at the International American Society of Hypertension 17th Scientific Sessions. Belo Horizonte, Brazil; August 5–8, 2009.

39.

Lima AM, Xavier CH, Santos RAS, et al.: Central activation of the ACE2-Ang-(1-7)-Mas axis markedly reduces the tachycardia evoked by acute stress exposure. Hypertension 2009, 54:e98.CrossRef

40.

Feng Y, Xia H, Lazartigues E: Alteration of baroreflex and autonomic function precedes the development of high blood pressure in angiotensin-converting enzyme 2 deficient mice. Hypertension 2009, 54:e97.CrossRef

41.

Xia H, Feng Y, Seth D, et al.: Impaired baroreflex and autonomic function in ACE2 knockout mice. Hypertension 2008, 52:e80.CrossRef

42.

Zheng H, Liu X, Moser JS, et al.: Gene transfer of angiotensin converting enzyme 2 to the paraventricular nucleus improves attenuated nitric oxide mechanism in rats with chronic heart failure. FASEB J 2009, 23:956.2.

43.

Gao L, Farrar R, Wang W, et al.: Selective over expression of central ACE2 prevents baroreflex dysfunction in the chronic heart failure. FASEB J 2009, 23:610.2.

44.

Villela DC, Verano TB, Campagnole-Santos MJ, et al.: Changes in the baroreflex control of heart rate produced by central infusion of a novel ACE2 product peptide, Ala1-Ang-(1-7). [abstract No. 1072]. Presented at the International American Society of Hypertension 17th Scientific Sessions. Belo Horizonte, Brazil; August 5–8, 2009.

45.

Zanzinger J: Role of nitric oxide in the neural control of cardiovascular function. Cardiovasc Res 1999, 43:639–649.CrossRefPubMed

46.

Zanzinger J, Czachurski J: Chronic oxidative stress in the RVLM modulates sympathetic control of circulation in pigs. Pflugers Arch 2000, 439:489–494.CrossRefPubMed

47.

Gao L, Wang W, Li YL, et al.: Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res 2004, 95:937–944.CrossRefPubMed

48.

Xia H, Cai Y, Bindom S, et al.: ACE2 gene deletion mediates an age-dependent increase in oxidative stress in the central nervous system. Hypertension 2009, 54:e98.CrossRef

Titel: Angiotensin-Converting Enzyme 2: Central Regulator for Cardiovascular Function
verfasst von: Huijing Xia
Eric Lazartigues
Publikationsdatum: 01.06.2010
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 3/2010
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-010-0105-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Wie der Klimawandel gefährliche Pilzinfektionen begünstigt

24.05.2024 Candida-Mykosen Nachrichten

Dass sich invasive Pilzinfektionen in letzter Zeit weltweit häufen, liegt wahrscheinlich auch am Klimawandel. Ausbrüche mit dem Hefepilz Candida auris stellen eine zunehmende Gefahr für Immungeschwächte dar – auch in Deutschland.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Sleep Apnea and Cardiovascular Disease

Obstructive Sleep Apnea and Hypertension

The Prognostic Significance of Heart Rate for Cardiovascular Disease and Hypertension

ASTRALogy: Unrealistic Expectations?

Renal Nerves in the Maintenance of Hypertension: A Potential Therapeutic Target